STOK
Stoke Therapeutics Inc

1,003
Mkt Cap
$1.88B
Volume
645,697.00
52W High
$38.69
52W Low
$5.35
PE Ratio
50.93
STOK Fundamentals
Price
$33.61
Prev Close
$32.98
Open
$32.52
50D MA
$30.02
Beta
1.28
Avg. Volume
1.19M
EPS (Annual)
-$1.65
P/B
6.01
Rev/Employee
$285,585.94
Loading...
Loading...
News
all
press releases
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·9h ago
News Placeholder
More News
News Placeholder
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK
Redmile Group LLC lessened its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 2.5% in the second quarter, according to the company in its most recent 13F filing with...
MarketBeat·5d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at...
MarketBeat·5d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 13,430 shares of Stoke Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 3,978 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 3,978 shares of the business's stock in a transaction that occurred on Monday, December 8th. The shares...
MarketBeat·6d ago
News Placeholder
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
Key PointsBarry Ticho, Chief Medical Officer of Stoke Therapeutics, sold 5,358 shares for a transaction value of $167,115.04 at a weighted average price of $31.19 per share in December...
Nasdaq News: Markets·6d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4% - Time to Buy?
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 12.4% - Time to Buy...
MarketBeat·7d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1% - What's Next?
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1% - Here's Why...
MarketBeat·7d ago
News Placeholder
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK
Marshall Wace LLP lifted its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 7.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange...
MarketBeat·8d ago
News Placeholder
STOK Crosses Above Average Analyst Target
In recent trading, shares of Stoke Therapeutics Inc (Symbol: STOK) have crossed above the average analyst 12-month target price of $31.62, changing hands for $33.00/share. When a stock reaches the...
Nasdaq News: Markets·8d ago
<
1
2
...
>

Latest STOK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.